Related Articles
Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis
An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.
Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
Two patients with psoriatic arthritis treated with TNF-alpha inhibitor therapy develop the multisystem disease
Case Report: Pulmonary Sarcoid-Like Reaction in Patient Treated with Etanercept
Sarcoidosis is a multisystem disease characterized by noncaseating granulomas in affected tissues, mostly involving the lungs and lymph nodes.1,2 The etiology of sarcoidosis remains unknown but is thought to be due to an inflammatory response to an antigen exposure in genetically predisposed individuals.1 Tumor necrosis factor-α (TNF‑α), a pro-inflammatory cytokine, plays an essential role in…
Case Report: Sarcoidosis in Patient with History of IgG4-Related Disease
Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as…